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Background/aim: The aim of our study was to compare the efficacy and the safety of the FLOT and the modified DCF (mDCF)
regimens in patients with metastatic gastric (GC) and gastroesophageal junction (GEJ) adenocarcinoma as first-line treatment.
Materials and methods: The medical records of 72 patients were retrospectively reviewed. Survivals and hematological adverse events
of the patients were examined. Factors affecting survivals were analyzed in univariate analysis. A multivariate analysis was performed
with the factors contributing to survivals in univariate analysis.
Results: The median PFS (mPFS) was 10.1 months (95% CI, 6.8–13.4) in the FLOT arm (n = 33) and 7.4 months (95% CI, 9.1–21.6) in
the mDCF arm (n = 39) (p = 0.041). The median OS (mOS) was 12.9 months (95% CI, 9.7–16.1) in the FLOT arm and 15.4 months (95%
CI, 9.1–21.6) in the mDCF arm (p = 0.622). It was found that all grade neutropenia was 51.3% vs. 72.7% (p = 0.063), febrile neutropenia
was 8.3% vs. 6.3% (p = 0.743), and thrombocytopenia was 48.7% vs. 51.5% (p = 0.813) in the FLOT and mDCF arms, respectively.
Anemia was 59% in the FLOT arm and 100% in the mDCF arm (p < 0.001). Grade 3-4 anemia was 7.7% in the FLOT arm and 24.2%
in the mDCF arm (p = 0.052).
Conclusion: It was shown that the mPFS was significantly increased in the FLOT arm compared to the mDCF arm as the first-line
treatment in patients with metastatic GC and GEJC. Hematological adverse events were more favorable in the FLOT arm than in the
mDCF arm.
Key words: FLOT, gastric cancer, gastroeosephageal cancer, modified DCF

1. Introduction
Gastric cancer is the fifth most common malignancy
worldwide, and is the third leading cause of cancerrelated deaths according to GLOBOCAN 2018 [1].
Approximately 31% of the patients at the time of diagnosis
are in the metastatic stage, and it was reported that
1-year survival was 22.9% [2]. In metastatic disease, the
aim is to prolong the overall survival (OS) and improve
the quality of life. Therefore, researching and comparing
effective chemotherapy regimens with tolerable side effect
profiles is an area of research

that attracts the attention of
clinicians. Trials of combination regimens have enabled
the rapid development of treatment protocols [3–8]. In
the phase III TAX-325 trial, it was found that median

time to tumor progression (mTTP) (5.6 months vs. 3.7
months; HR 1.47; 95% CI, 1.19–1.82; p < 0.001) and mOS
(9.2 months vs. 8.6 months; HR 1.29; 95% CI, 1.00–1.60;
p = 0.02) were significantly improved in favor of the DCF
arm compared to the CF arm. The objective response rate
was 36.7% in the DCF arm. However, grade 3-4 adverse
events were 69% in the DCF arm and 59% in the CF arm.
Notably, this discordant adverse event profile was also
observed to be reflected in compliance with treatment [9].
Many modification trials have been carried out to increase
patient tolerance without reducing the effectiveness of the
treatment [10–14].
The FLOT regimen proved its efficacy in a perioperative
setting with the FLOT4 trial in locally advanced resectable
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gastric and gastroesophageal adenocarcinoma patients
[15]. However, there is a limited number of FLOT studies
in patients with metastatic GC. In the three-armed
AIO-FLOT3 trial, arm B consisted of limited mGC,
and arm C consisted of extensive mGC patients. In the
arm B, improved survival was shown in the group that
underwent surgery after neoadjuvant FLOT therapy. In
the arm C, mPFS was 6.3 months (95% CI, 5.0–7.6), and
mOS was 10.7 months (95% CI, 9.1–12.8) [16]. In another
phase 2 study with mGC patients, FLOT efficacy was
demonstrated. In the study, 54 patients were treated, and
93% of the patients had metastatic disease. The objective
response rate (ORR) was 57.7%, median progressionfree survival (mPFS) was 5.2 months, and mOS was
11.1 months. Grade 3-4 neutropenia was observed in 26
(48.1%) patients [17]. Although both FLOT and mDCF
regimens contain docetaxel, 5-FU and platinum, their
adverse event profiles and efficacy might be different.
Numerically higher response rate and overall survival,
and lower grade 3-4 toxicity rate with the FLOT regimen
in the phase II study compared to those of with the DCF
regimen in the TAX325 study raised the question of
whether the FLOT regimen might be a more tolerable and
effective regimen than the DCF regimen.
The purpose of our study was to compare the efficacy
and safety of the mDCF and the FLOT regimens as a
first-line treatment in patients with metastatic gastric
and
gastroesophageal
junction
adenocarcinoma
retrospectively.
2. Materials and methods
2.1. Patients and treatment protocols
In the study, patients who were admitted to departments
of medical oncology in Gazi University and Hacettepe
University between October 2013–February 2020 and
diagnosed with mGC/mGEJC were reviewed. Inclusion
criteria were defined as; >18 years of age, de novo or
recurrent metastatic disease, availability of all patient
records, taking FLOT or mDCF regimens as a firstline treatment in metastatic disease, HER2 negativity
(immunohistochemistry-IHC 0, IHC 1+, in situ
hybridization-ISH negative). Exclusion criteria were
defined as; secondary malignancy, non-adenocarcinoma
histological subtypes or HER2 positivity (IHC3+, ISH
positive). Seventy-two patients were included in the study.
Diagnosis date, treatments received, treatment start and
end dates, adverse events follow-ups, complete blood
count, and biochemistry analysis were obtained from the
patient records. Progression-free survival was defined as
the time in months from first-line treatment initiation to
progression (CT, PET-CT), intolerable toxicity, or death.
OS was defined as the time in months from diagnosis of
metastatic disease to death or patient’s last visit.
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The mDCF regimen was used as docetaxel 60 mg/m2
(1-h intravenous infusion) plus cisplatin 60mg/m2 (2-h
intravenous infusion) on day 1, followed by 5-fluorouracil
600 mg/m2/day (continuous intravenous infusion) for 5
days every 3 weeks in our institutions. The FLOT regimen
was used as docetaxel 50 mg/m2 (1-h intravenous infusion)
plus oxaliplatin 85 mg/m2 (2-h intravenous infusion) plus
folinic acid 200 mg/m2 (2-h intravenous infusion) on
day 1 and followed by 5-fluorouracil 2600 mg/m2 (24-h
intravenous infusion) every 2 weeks.
Ethics committee approval of the study was obtained
from Gazi University Review Board (01.12.2020, 2021-28).
2.2. Statistical analysis
All statistical analyses were performed using SPSS version
22.0. Descriptive statistical analysis was performed to
show the distribution of variables in the population. Nonnormally distributed continuous variables were reported
using the median (interquartile range), and categorical
variables were reported using the Pearson chi-square
test. A Kaplan-Meier test was used to generate survival
curves, and a log-rank test was used to compare OS
and PFS results. A univariate analysis was performed to
determine the contribution of age, gender, metastatic
regions, number of metastatic sites, primary tumor
localization, tumor differentiation, mucinosis, ECOG PS
and chemotherapy on patients OS and PFS. A multivariate
analysis was performed for variables that had significant
contributions to survival in univariate analysis, and for
variables that were thought to be clinically significant. All
statistical tests were 2-sided (2-sided), and the significance
value was accepted as p < 0.05.
3. Results
The study included 72 patients diagnosed with recurrent/
de novo metastatic GC/GEJC and administered mDCF (n
= 33) or FLOT (n = 39) regimens as a first-line treatment.
Eleven patients (15.3%) had recurrent metastatic disease,
and 61 patients (84.7%) had de novo metastatic disease in
the whole cohort. It was observed that the tumor originated
from GEJ and cardia in 27.8% (n = 20) of the patients. The
most common metastasis sites were peritoneum [51.4% (n
= 37)], liver [43.1% (n = 31)] and bone [16.7% (n = 12)],
respectively. The clinicopathological characteristics of the
patients in the modified DCF and FLOT groups are shown
in Table 1.
The mPFS was 10.1 months (95% CI, 6.8–13.4) in the
FLOT arm and 7.4 months (95% CI, 5.5-9.3) in the mDCF
arm, and the difference was statistically significant (p =
0.041) (Figure 1). The analysis of variables that may affect
progression-free survival was examined. The mPFS was
6.3 months (95% CI, 5.0–7.5) in the group without liver
metastasis, and 13.1 months (95% CI, 7.3–18.8) in the
group with liver metastasis (p = 0.029). The mPFS was 13.9
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Table 1. Clinicopathologic characteristics of patients.
Variable

mDCF

FLOT

p-value

Number of patients, n (%)

33 (45.8)

39 (54.2)

-

Median age, years (IQR)

57 (50–62)

58 (47–66)

0.671

≥65 years old

7 (21.2)

28 (71.8)

0.495

<65 years old

26 (78.8)

11 (28.2)

Male

27 (81.8)

24 (61.5)

Female

6 (18.2)

15 (38.5)

Nonmetastatic

9 (27.3)

2 (5.1)

Metastatic

24 (72.7)

37 (94.7)

Liver

14 (42.4)

17 (43.6)

0.921

Peritoneum

22 (66.7)

15 (38.5)

0.017

Bone

8 (24.2)

4 (10.3)

0.113

Others

18 (54.5)

19 (48.7)

0.622

<2

12 (36.4)

23 (59)

0.056

≥2

21 (63.6)

16 (41)

Cardia + EGJ

7 (21.2)

13 (33.3)

0.253

Fundus + Corpus

17 (51.5)

16 (41)

0.373

Antrum + Pylorus

9 (27.3)

10 (25.6)

0.876

Well + Moderate

7 (36.8)

9 (30)

0.619

Poor

12 (63.2)

21 (70)

0.619

Mucinous tumour, n (%)

10 (30.3)

17 (43.6)

0.246

0–1

32 (97)

37 (94.9)

0.657

2

1 (3)

2 (5.1)

Elderly, n (%)

Sex, n (%)
0.059

Metastatic condition at initial diagnosis, n (%)
0.009

Metastatic site, n (%)

No. of metastatic sites, n (%)

Primary tumor localization, n (%)

Differentiation, n (%)

ECOG PS, n (%)

months (95% CI, 8.4–19.3) months in the group without
peritoneal metastasis and 6.2 months (95% CI, 5.6–6.7) in
the group with peritoneal metastasis (p < 0.001). The mPFS
was 13.1 months (95% CI, 5.9–20.2) in the group with
number of metastatic sites <2, and 6.6 months (95% CI,
5.3–7.9) in the group with number of metastatic sites ≥2 (p
= 0.005). It was found that the mPFS was 9.3 months (95%
CI, 7.1–11.6) in the ECOG PS of 0–1 group and 3.3 months
(95% CI, 0.6–6.0) in the ECOG PS of 2 group (p = 0.002).
A multivariate analysis was performed with variables that
had a significantly positive contribution to PFS in the
univariate analysis. It was observed that in the multivariate

analysis, ECOG PS of 2 (HR 10.38; 95% CI, 2.15–49.9; p
= 0.004) and number of metastatic sites ≥2 (HR 1.93; 95%
CI, 1.00–3.72; p = 0.048) increased the risk of progression.
In the multivariate analysis, the FLOT regimen was devoid
of the positive contribution to the risk of progression (HR
0.71; 95% CI, 0.39–128; p = 0.262) (Table 2).
The mOS was 15.4 months (95% CI, 9.1–21.6) in
the mDCF arm and 12.9 months (95% CI, 9.7–16.1) in
the FLOT arm, and the difference was not statistically
significant (p = 0.622) (Figure 2). The analysis of variables
that may affect the overall survival was examined. It was
observed that the mOS was 10.7 months (95% CI, 9.3–
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Table 2. Univariate and multivariate cox regression models to estimate PFS.

Variable

Progression-free survival

Multivariate analysis

mPFS (months)

95% CI

Log-Rank

HR

95% CI

p-value

≥65 years old

7.8

5.3–10.2

0.742

-

-

-

<65 years old

9.8

5.3–14.4

-

-

-

Male

7.8

5.5–10.0

-

-

-

Female

13.9

6.5–21.2

-

-

-

*Liver

13.1

7.3–18.8

0.029

0.55

0.30–10.1

0.057

**Peritoneum

6.2

5.6–6.7

<0.001

1.74

0.91–3.35

0.093

Bone

6.2

5.3–7.0

0.064

-

-

-

Others

7.9

5.9–9.8

0.210

-

-

-

<2

13.1

5.9-20.2

0.005

Ref

≥2

6.6

5.3-7.9

1.93

1.00–3.72

0.048

Cardia + EGJ

6.4

5.6–7.2

-

-

-

Fundus + Corpus

7.9

5.0-10.8

-

-

-

Antrum + Pylorus

9.8

8.3–11.2

-

-

-

Well + Moderate

9.3

4.8–13.8

-

-

-

Poor

8.7

4.2–13.2

-

-

-

Mucinous tumour

6.4

3.3–9.4

0.740

-

-

-

0-1

9.3

7.1–11.6

0.002

Ref

2

3.3

0.6-6.0

2.15–49.9

0.004

mDCF

7.4

5.5–9.3

FLOT

10.1

6.8–13.4

0.39–1.28

0.262

Elderly

Sex
0.278

Metastatic site

No. of metastatic sites

Primary tumor localization
0.743

Differentiation (n = 49)
0.900

ECOG PS
10.38

First-line chemotherapy
0.041

Ref
0.71

*The reference of this analysis is “no liver metastasis”.
**The reference of this analysis is “no peritoneal metastasis”.

12.0) in the group with bone metastasis, 17.2 months (95%
CI, 8.7–25.7) in the group without bone metastasis (p =
0.005). The mOS was 25.5 months (95% CI, 8.2–42.9) in
the group with number of metastatic sites <2, and 12.3
months (95% CI, 9.2–15.5) in the group with number
of metastatic sites ≥2 (p = 0.019). The mOS was 15.2
months (95% CI, 12.5–17.8) in ECOG PS of 0–1 group
and 5 months (95% CI, 0–10.6) in ECOG PS of 2 group
(p < 0.001). A multivariate analysis was performed with
variables that had a significantly positive contribution to
OS in the univariate analysis and chemotherapy variable
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(mDCF or FLOT), which was thought to be clinically
significant. It was found that in the multivariate analysis,
bone metastasis (HR 2.56; 95% CI, 1.22–5.35; p = 0.012)
and ECOG PS of 2 (HR 8.78; 95% CI, 2.44–31.5; p = 0.001)
increased the risk of death. However, the FLOT regimen
did not reduce the risk of death in the multivariate analysis
(HR 1.47; 95% CI, 0.79–2.72; p = 0.219) (Table 3). After
the progression under the first-line treatment, 23.3% (n =
7) of the patients in the FLOT arm, and 76.7% (n = 23)
in the mDCF arm received second-line chemotherapy (p
< 0.001). As a second-line therapy, 77.8% (n = 21) of the
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patients in the mDCF arm, and 22.2% (n = 6) of the FLOT
arm received combined chemotherapy (p < 0.001) (Table
4). In our study, two patients underwent metastasectomy
in the mDCF arm, and the overall survivals of these
patients were calculated as 39.6 months and 32.6 months.
The disease control rate (DCR) was 84.6% in the FLOT
arm and 72.7% in the mDCF arm (p = 0.216). The ORR
was 59% in the FLOT arm and 48.5% in the mDCF arm (p
= 0.373). The complete response rate was 5.1% vs. 6.1% (p
= 0.863), and the partial response rate was 53.8% vs. 42.4%
(p = 0.334), in the FLOT arm and mDCF arm, respectively.
The progressive disease rate was 15.4% in the FLOT arm,
and 27.3% in the mDCF arm (p = 0.216) (Table 5).
It was found that neutropenia was 51.3% vs. 72.7% (p =
0.063), febrile neutropenia was 8.3% vs. 6.3% (p = 0.743),

and thrombocytopenia was 48.7% vs. 51.5% (p = 0.813), in
the FLOT and mDCF arms, respectively. Anemia was 59%
in the FLOT arm and 100% in the mDCF arm (p < 0.001).
However, grade 3-4 anemia was 7.7% in the FLOT arm and
24.2% in the mDCF arm (p = 0.052). It was observed that
the rate of using primary GCSF prophylaxis was 84.6% in
the FLOT arm and 90.9% in the mDCF arm (p = 0.421).
The rate of using secondary GCSF prophylaxis was 5.1% in
the FLOT arm and 18.2% in the mDCF arm (p = 0.079).
The median duration of follow-up was 15.4 months in the
mDCF arm and 9.4 months in the FLOT arm (p = 0.005).
It was found that the treatment discontinuation rates were
8.1% vs. 3.0% (p = 0.361), and the rate of at least one dose
reduction was 24.3% vs. 45.5% (p = 0.063) in the FLOT
and mDCF arms, respectively. The delay of at least one

Table 3. Univariate and multivariate cox regression models to estimate OS.

Variable
Elderly
≥65 years old
<65 years old
Sex
Male
Female
Metastatic site
Liver
Peritoneum
*Bone
Others
No. of metastatic sites
<2
≥2
Primary tumor localization
Cardia + EGJ
Fundus + Corpus
Antrum + Pylorus
Differentiation (n=49)
Well + Moderate
Poor
Mucinous tumour (n = 27)
ECOG PS
0-1
2
First-line chemotherapy
mDCF
FLOT

Overall survival

Multivariate analysis

mOS (months)

95% CI

Log-Rank

HR

95% CI

p-value

12.3
14.9

0–26.9
12.6–17.2

0.333

-

-

-

12.9
15.4

8.1–17.7
11.9–18.8

0.317

-

-

-

23.6
10.9
10.7
13.3

9.9–37.2
4.6–17.2
9.3–12.0
9.9–16.7

0.113
0.294
0.005
0.194

2.56
-

1.22–5.35
-

0.012
-

25.5
12.3

8.2–42.9
9.2–15.5

0.019

Ref
1.75

0.92–3.33

0.088

13.9
15.2
14.9

9.1–18.6
11.2–19.2
9.9–20

-

-

-

19.3
13.9
14.9

8.0–30.7
10.9–16.9
4.5–25.4

0.968

-

-

-

15.2
5.0

12.5–17.8
0–10.6

<0.001

Ref
8.78

2.44–31.5

0.001

15.4
12.9

9.1–21.6
9.7–16.1

0.622

Ref
1.47

0.79–2.72

0.219

0.917

0.745

*The reference of this analysis is “no bone metastasis”.
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dose was 66.7% in the mDCF arm and 32.4% in the FLOT
arm (p = 0.004) (Table 6).
4. Discussion
In our study, it was revealed that the mPFS was significantly

increased in the FLOT arm compared to the mDCF
arm as a first-line treatment in patients with mG/mGEJ
adenocarcinoma. The mOS’s in both FLOT and mDCF
arms were similar. It was also found that the ORR was

Figure 1. Progression-free survival (PFS) in patients with
metastatic GC and GEJC with first-line treatment.

Figure 2. Overall survival (OS) in patients with metastatic GC
and GEJC.

Table 4. Second-line treatment exposure.
Variable, n (%)

mDCF

FLOT

p-value

Second-line treatment

23 (76.7)

7 (23.3)

<0.001

Combined chemotherapy regimen

21 (77.8)

6 (22.2)

<0.001

Single agent chemotherapy

2 (6.1)

1 (2.6)

0.437

Table 5. Best response rate analyses of patient with first-line treatment.

1564

Parameter

mDCF

FLOT

p-value

Disease control rate, n (%)

24 (72.7)

33 (84.6)

0.216

Objective response rate, n (%)

16 (48.5)

23 (59)

0.373

Complete response, n (%)

2 (6.1)

2 (5.1)

0.863

Partial response, n (%)

14 (42.4)

21 (53.8)

0.334

Stable disease, n (%)

8 (24.2)

10 (25.6)

0.891

Progressive disease, n (%)

9 (27.3)

6 (15.4)

0.216

Median time to best response, months (min-max)

3.6 (0.69–9.8)

3.3 (1.6–14.7)

0.439

GÜRLER et al. / Turk J Med Sci
Table 6. Treatment exposure and hematologic advers events.
mDCF

FLOT

P value

Toxicities, n (%)

Grade 3-4 All

Grade 3-4 All

Grade 3-4 All

Neutropenia

6 (18.2)

24 (72.7)

7 (17.9)

20 (51.3)

0.980

0.063

Anemia

8 (24.2)

33 (100)

3 (7.7)

23 (59)

0.052

<0.001

Thrombocytopenia

2 (6.1)

17 (51.5)

1 (2.6)

19 (48.7)

0.459

0.813

Febrile neutropenia

2 (6.3)

3 (8.3)

0.743

Primary GCSF prophylaxis, n (%)

30 (90.9)

33 (84.6)

0.421

Secondary GCSF prophylaxis, n (%)

6 (18.2)

2 (5.1)

0.079

Median duration of follow-up, months (min-max)

15.4 (0.69–74.55)

9.4 (1.64–32.62)

0.005

Median duration of 1st line treatment, months (min-max) 7.43 (0.69–74.55)

7.46 (1.64–32.62)

0.928

≥1 dose reduction, n (%)

15 (45.5)

9 (24.3)

0.063

≥1 dose delay (%), n (%)

22 (66.7)

12 (32.4)

0.004

Treatment cessation, n (%)

1 (3)

3 (8.1)

0.361

Parameters

clinically meaningfully improved in FLOT arm compared
to mDCF arm. Regarding hematological adverse events,
anemia was statistically significantly less frequent, and
hematological adverse events other than anemia were
clinically meaningfully less frequent in the FLOT arm than
those of in the mDCF arm.
Triplet regimens are the backbone of mGC. In the TAX325 trial, it was reported that mOS was 9.2 months (95%
CI, 8.4–10.6) and mPFS was 5.6 months (95% CI, 4.9–5.9)
in the DCF arm [9]. In a phase 2 study in which DCF and
ECF regimens were compared, it was found that mOS was
12.5 months (95% CI, 11.2–15.8) and mPFS was 7.5 months
(95% CI, 6.2–9.7) in the DCF arm [18]. In a meta-analysis
including 24 mDCF regimen studies, it was observed that
mOS was 12.3 months (95% CI, 10.6–14.3) and mPFS was
7.2 months (95% CI, 5.9–8.8) in the pooled analysis [19].
In a phase II study with the FLOT regimen, it was reported
mOS was 11.1 months and mPFS was 5.2 months [17]. In
a study conducted with mFLOT regimen, mPFS was 4.4
months (95% CI, 2.9–5.9) [20]. In the AIO-FLOT3 study,
which was a three-arm study, the B arm included limited
metastatic gastric adenocarcinoma patients and the C
arm included patients with extensive metastatic gastric
adenocarcinoma. In the arm B, mOS was 15.9 months
(95% CI, 7.1–22.9), and mPFS was 8.4 months (95% CI,
4.1–10.4) in patients not undergoing surgery. In the arm C,
mOS was 10.7 months (95% CI, 9.1–12.8), and mPFS was
6.3 months (95% CI, 5.0–7.6) [16]. In our study, mPFS was
7.4 months (95% CI, 5.5–9.3) in the mDCF arm and 10.1
months (95% CI, 6.8–13.4) in the FLOT arm. The mPFS in
the mDCF arm was similar to those of in the DCF pivotal
study and mDCF studies [9,19]. The mPFS in FLOT arm

was numerically higher than those of in previous FLOT
studies [16, 17]. The contribution of number of metastatic
sites <2 and ECOG PS of 0–1 on PFS was determined in
both univariate and multivariate analyses. The positive
effect of the FLOT regimen on the risk of progression in
the multivariate analysis lost its significance. In our study,
it was found that the mOS was 15.4 months (95% CI,
9.1–21.6) in the mDCF arm and 12.9 months (95% CI,
9.7–16.1) in the FLOT arm, and the difference was not
statistically significant (p = 0.622). The mOS in the mDCF
arm in our study was numerically higher than the mOS
in the pivotal DCF study, the mOS in previous mDCF
studies, and the mOS in prospective and retrospective
DCF studies [9,18,21]. In our study, although the mPFS
was significantly increased in the FLOT arm compared to
the mDCF arm, it was thought that there might be some
reasons why mOS’s in both arms were similar. In our study,
the rate of the second-line chemotherapy was found to be
significantly higher in the mDCF arm than in the FLOT
arm. The rate of using combination chemotherapy as a
second-line chemotherapy was significantly higher in the
mDCF arm than that of in the FLOT arm. This difference in
the use of the second-line chemotherapy might be shown
as one of the reasons why the significant improvement in
PFS did not remain as an advantage in OS. The widespread
use of the concept of oligometastatic gastric cancer and
local treatment methods might be shown as one of the
reasons why patients with a single metastasis area had
increased OS [22]. In our study, two patients in the mDCF
arm underwent a metastasectomy. The overall survivals of
these patients were over 30 months, and it is thought that
it might contribute to prolonged OS in the mDCF arm.
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In our study, it was found that the ORR in the FLOT
arm (59%) was numerically lower than that of in arm B
(66.7%), and numerically higher than that of in arm C
(43.3%) of the AIO-FLOT3 study. Our study found that
the ORR in the FLOT arm was numerically higher than
that of in the pivotal DCF study (37%). In our study, the
DCR in the FLOT arm (84.6%) and the DCR in arm
B of the AIO-FLOT3 study (83.4%) were similar, but
the DCR in our study was numerically higher than the
DCR in arm C of the AIO-FLOT3 study (77.9%) [16].
The median duration of follow-up in our study was
significantly higher in the mDCF arm than in the FLOT
arm. One of the reasons of this discrepency migh be that
the mDCF regimen is older than the FLOT regimen, and
it was started earlier. In a phase II study conducted in
Egypt, in which 72% of patients had metastatic disease,
the ORR was %55.3 [23]. Our results were consistent with
this phase II study.
High neuropenia rate in the pivotal DCF study directed
us to perform GCSF prophylaxsis [24]. In our study, the
application rates of primary GCSF and secondary GCSF
prophylaxsis were similar in mDCF and FLOT arms.
Anemia was significantly lower in the FLOT arm than that
of in the mDCF arm. Other hematological adverse events
were clinically significantly lower in the FLOT arm than
that of in the mDCF arm. Grade 3-4 neutropenia was
lower in our study (17.9%) than in arm B (46.3%) and
arm C (42.1%) of the AIO-FLOT3 study. However, this
study did not provide information about the application
of GCSF prophylaxsis. Grade 3-4 thrombocytopenia and
anemia in our study were higher than in the AIO-FLOT3
study. High GCSF application rates in our study might
be count a possible explanation for that via a competitive
microenvironment in bone marrow [16].
Our study has some limitations and strengths. Firstly,
our study is a retrospective study with a limited number
of patients. Secondly, adverse events data other than
hematological adverse events could not be obtained
completely. Nevertheless, it might be a guide in clinical
practice in terms of presenting real-life data of detailed

hematological toxicity profile comparing the FLOT and
mDCF regimens.
In conclusion, it was revealed that mPFS was
significantly increased in the FLOT arm compared to the
mDCF arm in patients with mG/mGEJ adenocarcinoma as
first-line treatment. The mOS’s in both FLOT and mDCF
arms were similar. Favorurable hematological adverse
events were obtained in the FLOT arm than those of in the
mDCF arm. As far as we can reach, there is no randomized
controlled prospective trial performed with FLOT
regimen in metastatic GC and GEJC patients. In addition,
to our best knowledge, this is the first retrospective study
comparing the mDCF and the FLOT regimens as first-line
treatment in mGC/mGEJC. The FLOT regimen might be
considered an option as a first-line treatment in metastatic
GC/GEJC patients with increased PFS and increased
tolerability compared to the mDCF regimen. Further
investigations of randomized controlled prospective trials
with large patient groups are needed to provide a better
knowledge on this issue.
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